STOCKHOLM : Hygiene products group Essity said on Wednesday it has initiated a strategic review of its stake in China-based Vinda and its Consumer Tissue Private Label Europe business.
The Swedish company said in a statement the aim of the review is to reduce its Consumer Tissue division's share of group sales. "The strategic review includes exploring different options and may result in divestments, although no such decisions have yet been taken," it said.Vinda in 2022 accounted for 16 per cent of Essity's 156 billion Swedish crowns turnover, while the Consumer Tissue Private Label Europe business represented 6 per cent.
Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder: